These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35013206)

  • 1. Robust and durable serological response following pediatric SARS-CoV-2 infection.
    Renk H; Dulovic A; Seidel A; Becker M; Fabricius D; Zernickel M; Junker D; Groß R; Müller J; Hilger A; Bode SFN; Fritsch L; Frieh P; Haddad A; Görne T; Remppis J; Ganzemueller T; Dietz A; Huzly D; Hengel H; Kaier K; Weber S; Jacobsen EM; Kaiser PD; Traenkle B; Rothbauer U; Stich M; Tönshoff B; Hoffmann GF; Müller B; Ludwig C; Jahrsdörfer B; Schrezenmeier H; Peter A; Hörber S; Iftner T; Münch J; Stamminger T; Groß HJ; Wolkewitz M; Engel C; Liu W; Rizzi M; Hahn BH; Henneke P; Franz AR; Debatin KM; Schneiderhan-Marra N; Janda A; Elling R
    Nat Commun; 2022 Jan; 13(1):128. PubMed ID: 35013206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.
    Woudenberg T; Pelleau S; Anna F; Attia M; Donnadieu F; Gravet A; Lohmann C; Seraphin H; Guiheneuf R; Delamare C; Stefic K; Marlet J; Brochot E; Castelain S; Augereau O; Sibilia J; Dubos F; Meddour D; Guen CG; Coste-Burel M; Imbert-Marcille BM; Chauvire-Drouard A; Schweitzer C; Gatin A; Lomazzi S; Joulié A; Haas H; Cantais A; Bertholon F; Chinazzo-Vigouroux MF; Abdallah MS; Arowas L; Charneau P; Hoen B; Demeret C; Werf SV; Fontanet A; White M
    EBioMedicine; 2021 Aug; 70():103495. PubMed ID: 34304047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.
    Zheng J; Deng Y; Zhao Z; Mao B; Lu M; Lin Y; Huang A
    Cell Mol Immunol; 2022 Feb; 19(2):150-157. PubMed ID: 34645940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variant-specific antibody profiling for tracking SARS-CoV-2 variant infections in children and adolescents.
    Kuthning D; Raafat D; Holtfreter S; Gramenz J; Wittmann N; Bröker BM; Meyer-Bahlburg A
    Front Immunol; 2024; 15():1434291. PubMed ID: 39257574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination.
    Sariol CAA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina-Rodríguez A; Cruz L; Stone ETT; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AKK; Brien JDD; Espino AMM
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant.
    Parry H; Tut G; Bruton R; Faustini S; Stephens C; Saunders P; Bentley C; Hilyard K; Brown K; Amirthalingam G; Charlton S; Leung S; Chiplin E; Coombes NS; Bewley KR; Penn EJ; Rowe C; Otter A; Watts R; D'Arcangelo S; Hallis B; Makin A; Richter A; Zuo J; Moss P
    Elife; 2021 Sep; 10():. PubMed ID: 34586068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells.
    Wietschel KA; Fechtner K; Antileo E; Abdurrahman G; Drechsler CA; Makuvise MK; Rose R; Voß M; Krumbholz A; Michalik S; Weiss S; Ulm L; Franikowski P; Fickenscher H; Bröker BM; Raafat D; Holtfreter S
    Front Immunol; 2024; 15():1382911. PubMed ID: 38807606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence.
    Bean DJ; Monroe J; Liang YM; Borberg E; Senussi Y; Swank Z; Chalise S; Walt D; Weinberg J; Sagar M
    Sci Transl Med; 2024 Jun; 16(751):eado7588. PubMed ID: 38865483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.
    Guthmiller JJ; Stovicek O; Wang J; Changrob S; Li L; Halfmann P; Zheng NY; Utset H; Stamper CT; Dugan HL; Miller WD; Huang M; Dai YN; Nelson CA; Hall PD; Jansen M; Shanmugarajah K; Donington JS; Krammer F; Fremont DH; Joachimiak A; Kawaoka Y; Tesic V; Madariaga ML; Wilson PC
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity.
    Stanley AM; Aksyuk AA; Wilkins D; Green JA; Lan D; Shoemaker K; Tieu HV; Sobieszczyk ME; Falsey AR; Kelly EJ
    Front Immunol; 2024; 15():1401728. PubMed ID: 38827749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
    Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
    J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower Humoral and Cellular Immunity Following Asymptomatic SARS-CoV-2 Infection Compared to Symptomatic Infection in Education (The ACE Cohort).
    Hopkins G; Gomez N; Tucis D; Bartlett L; Steers G; Burns E; Brown M; Harvey-Cowlishaw T; Santos R; Lauder SN; Scurr M; Capitani L; Burnell S; Rees T; Smart K; Somerville M; Gallimore A; Perera M; Potts M; Metaxaki M; Krishna B; Jackson H; Tighe P; Onion D; Godkin A; Wills M; Fairclough L
    J Clin Immunol; 2024 Jun; 44(6):147. PubMed ID: 38856804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents.
    Tsang HW; Chua GT; To KKW; Wong JSC; Tu W; Kwok JSY; Wong WHS; Wang X; Zhang Y; Rosa Duque JS; Chan GCF; Chu WK; Pang CP; Tam PKH; Lau YL; Wong ICK; Leung WH; Yuen KY; Kwan MYW; Ip P
    Front Immunol; 2021; 12():797919. PubMed ID: 34975908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
    Glöckner S; Hornung F; Baier M; Weis S; Pletz MW; Deinhardt-Emmer S; Löffler B; The CoNAN Study Group
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection.
    Dowell AC; Butler MS; Jinks E; Tut G; Lancaster T; Sylla P; Begum J; Bruton R; Pearce H; Verma K; Logan N; Tyson G; Spalkova E; Margielewska-Davies S; Taylor GS; Syrimi E; Baawuah F; Beckmann J; Okike IO; Ahmad S; Garstang J; Brent AJ; Brent B; Ireland G; Aiano F; Amin-Chowdhury Z; Jones S; Borrow R; Linley E; Wright J; Azad R; Waiblinger D; Davis C; Thomson EC; Palmarini M; Willett BJ; Barclay WS; Poh J; Amirthalingam G; Brown KE; Ramsay ME; Zuo J; Moss P; Ladhani S
    Nat Immunol; 2022 Jan; 23(1):40-49. PubMed ID: 34937928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response.
    Mileto D; Fenizia C; Cutrera M; Gagliardi G; Gigantiello A; De Silvestri A; Rizzo A; Mancon A; Bianchi M; De Poli F; Cuomo M; Burgo I; Longo M; Rimoldi SG; Pagani C; Grosso S; Micheli V; Rizzardini G; Grande R; Biasin M; Gismondo MR; Lombardi A
    Emerg Microbes Infect; 2021 Dec; 10(1):2235-2243. PubMed ID: 34749573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.
    Roozendaal R; Solforosi L; Stieh DJ; Serroyen J; Straetemans R; Dari A; Boulton M; Wegmann F; Rosendahl Huber SK; van der Lubbe JEM; Hendriks J; Le Gars M; Dekking L; Czapska-Casey DN; Guimera N; Janssen S; Tete S; Chandrashekar A; Mercado NB; Yu J; Koudstaal W; Perez-Ruixo JJ; Sadoff J; Barouch DH; Schuitemaker H; Zahn R
    Nat Commun; 2021 Oct; 12(1):5877. PubMed ID: 34620860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2.
    Majdoubi A; Michalski C; O'Connell SE; Dada S; Narpala S; Gelinas J; Mehta D; Cheung C; Winkler DF; Basappa M; Liu AC; Görges M; Barakauskas VE; Irvine M; Mehalko J; Esposito D; Sekirov I; Jassem AN; Goldfarb DM; Pelech S; Douek DC; McDermott AB; Lavoie PM
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33720905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals.
    Klingler J; Lambert GS; Itri V; Liu S; Bandres JC; Enyindah-Asonye G; Liu X; Simon V; Gleason CR; Kleiner G; Chiu HP; Hung CT; Kowdle S; Amanat F; Lee B; Zolla-Pazner S; Upadhyay C; Hioe CE
    Front Immunol; 2021; 12():759688. PubMed ID: 34987505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.